Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Claudin 18.2-positive gastric cancer, drawn from the whole corpus: 12 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether zolbetuximab or PD-1 blockade should come first when both PD-L1 and claudin 18.2 are positive.
Tumours below the 75 percent threshold have no approved claudin 18.2 therapy.
Nausea and vomiting lead some patients to stop early.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Median progression-free survival 3.
A milestone in how this cancer is treated.
SPOTLIGHT OS 18.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.